<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:44:58Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10262995" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10262995</identifier>
        <datestamp>2023-06-15</datestamp>
        <setSpec>lwwopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Hypertension</journal-id>
              <journal-id journal-id-type="iso-abbrev">Hypertension</journal-id>
              <journal-id journal-id-type="publisher-id">HYP</journal-id>
              <journal-title-group>
                <journal-title>Hypertension (Dallas, Tex. : 1979)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0194-911X</issn>
              <issn pub-type="epub">1524-4563</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
                <publisher-loc>Hagerstown, MD</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10262995</article-id>
              <article-id pub-id-type="pmcid">PMC10262995</article-id>
              <article-id pub-id-type="pmc-uid">10262995</article-id>
              <article-id pub-id-type="pmid">37161796</article-id>
              <article-id pub-id-type="pmid">37161796</article-id>
              <article-id pub-id-type="art-access-id">00013</article-id>
              <article-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.123.20901</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>10061</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Metabolomic Profiles Associated With Blood Pressure Reduction in Response to the DASH and DASH-Sodium Dietary Interventions</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1707-7018</contrib-id>
                  <name>
                    <surname>Kim</surname>
                    <given-names>Hyunju</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0673-6823</contrib-id>
                  <name>
                    <surname>Appel</surname>
                    <given-names>Lawrence J.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1053-9478</contrib-id>
                  <name>
                    <surname>Lichtenstein</surname>
                    <given-names>Alice H.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wong</surname>
                    <given-names>Kari E.</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chatterjee</surname>
                    <given-names>Nilanjan</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4804-7583</contrib-id>
                  <name>
                    <surname>Rhee</surname>
                    <given-names>Eugene P.</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5442-8745</contrib-id>
                  <name>
                    <surname>Rebholz</surname>
                    <given-names>Casey M.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <aff id="aff1">Department of Epidemiology (H.K., L.J.A., C.M.R.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</aff>
                <aff id="aff2">Department of Biostatistics (N.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.</aff>
                <aff id="aff3">Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD (H.K., L.J.A., C.M.R.).</aff>
                <aff id="aff4">Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD (L.J.A., C.M.R.).</aff>
                <aff id="aff5">Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA (A.H.L.).</aff>
                <aff id="aff6">Metabolon, Research Triangle Park, Morrisville, NC (K.E.W.).</aff>
                <aff id="aff7">Nephrology Division and Endocrine Unit, Massachusetts General Hospital, Boston, MA (E.P.R.).</aff>
              </contrib-group>
              <author-notes>
                <corresp id="c1">Correspondence to: Casey M. Rebholz, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Suite 2-500, 2024 E Monument St, Baltimore, MD 21287. Email <email xlink:href="crebhol1@jhu.edu">crebhol1@jhu.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>10</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <volume>80</volume>
              <issue>7</issue>
              <fpage>1494</fpage>
              <lpage>1506</lpage>
              <history>
                <date date-type="received">
                  <day>6</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 The Authors.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p><italic toggle="yes">Hypertension</italic> is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution Non-Commercial-NoDerivs</ext-link> License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="hyp-80-1494.pdf"/>
              <abstract>
                <title>Background:</title>
                <p>The DASH (Dietary Approaches to Stop Hypertension) diets reduced blood pressure (BP) in the DASH and DASH-Sodium trials, but the underlying mechanisms are unclear. We identified metabolites associated with systolic BP or diastolic BP (DBP) changes induced by dietary interventions (DASH versus control arms) in 2 randomized controlled feeding studies—the DASH and DASH-Sodium trials.</p>
                <sec>
                  <title>Methods:</title>
                  <p>Metabolomic profiling was conducted in serum and urine samples collected at the end of diet interventions: DASH (n=219) and DASH-Sodium (n=395). Using multivariable linear regression models, associations were examined between metabolites and change in systolic BP and DBP. Tested for interactions between diet interventions and metabolites were the following comparisons: (1) DASH versus control diets in the DASH trial (serum), (2) DASH high-sodium versus control high-sodium diets in the DASH-Sodium trial (urine), and (3) DASH low-sodium versus control high-sodium diets in the DASH-Sodium trial (urine).</p>
                </sec>
                <sec>
                  <title>Results:</title>
                  <p>Sixty-five significant interactions were identified (DASH trial [serum], 12; DASH high sodium [urine], 35; DASH low sodium [urine], 18) between metabolites and systolic BP or DBP. In the DASH trial, serum tryptophan betaine was associated with reductions in DBP in participants consuming the DASH diets but not control diets (<italic toggle="yes">P</italic> interaction, 0.023). In the DASH-Sodium trial, urine levels of N-methylglutamate and proline derivatives (eg, stachydrine, 3-hydroxystachydrine, N-methylproline, and N-methylhydroxyproline) were associated with reductions in systolic BP or DBP in participants consuming the DASH diets but not control diets (<italic toggle="yes">P</italic> interaction, &lt;0.05 for all tests).</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>We identified metabolites that were associated with BP lowering in response to dietary interventions.</p>
                </sec>
                <sec>
                  <title>Registration:</title>
                  <p>URL: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03403166" ext-link-type="uri">https://www.clinicaltrials.gov/ct2/show/NCT03403166</ext-link>; Unique identifier: NCT03403166 (DASH trial). URL: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT00000608" ext-link-type="uri">https://www.clinicaltrials.gov/ct2/show/NCT00000608</ext-link>; Unique identifier: NCT00000608 (DASH-Sodium trial).</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>blood pressure</kwd>
                <kwd>dietary approaches to stop hypertension</kwd>
                <kwd>hypertension</kwd>
                <kwd>metabolic networks and pathways</kwd>
                <kwd>metabolomics</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>SDC</meta-name>
                  <meta-value>T</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text position="float">
              <caption>
                <title>Novelty and Relevance</title>
              </caption>
              <sec>
                <title>What Is New?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>The DASH diet reduces blood pressure. Yet, the pathways underlying the DASH diet and blood pressure reductions have yet to be elucidated.</p>
                  </list-item>
                  <list-item>
                    <p>Metabolites (eg, serum tryptophan betaine, urine N-methylglutamate, urine proline derivatives) and metabolic pathways were associated with blood pressure reduction in people consuming the DASH diet but not the control diet.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>What Is Relevant?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Using data from randomized feeding studies, we identified metabolites associated with changes in blood pressure in response to the DASH and DASH-Sodium diets.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>Clinical/Pathophysiological Implications?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Metabolites and metabolic pathways provide insights on formulating diet intervention strategies to reduce blood pressure.</p>
                  </list-item>
                </list>
              </sec>
            </boxed-text>
            <p>The DASH (Dietary Approaches to Stop Hypertension) diet is recommended for reducing blood pressure (BP) and risk of cardiovascular disease (CVD).<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> The DASH diet emphasizes the intake of fruits, vegetables, and low-fat dairy; includes a variety of protein sources such as poultry, fish, and legumes and nuts; and is low in red and processed meats and sugar-sweetened beverages. In the original DASH trial, the DASH diet significantly reduced systolic BP (SBP) and diastolic BP (DBP) more than the control diet.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> In the DASH-Sodium trial, the DASH diet reduced SBP and DBP at all sodium levels (high, moderate, and low), compared with the control diet.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> The reduction in BP was greater when the DASH diet was combined with a low-sodium intake than the DASH diet alone or low sodium alone. Yet, the pathways underlying the DASH diet and BP reductions have yet to be elucidated.</p>
            <p>We previously used global, untargeted metabolomic profiling to identify a panel of serum and urine metabolites that may be considered biomarkers of the DASH diets using specimens from the DASH and DASH-Sodium trials.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> Of the 97 serum metabolites that were significantly different between the DASH and control diet interventions in the DASH trial, 10 metabolites were the most influential in distinguishing among the 2 dietary patterns.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> These 10 metabolites included amino acids (N-methylproline and tryptophan betaine), xenobiotics (stachydrine, methyl glucopyranoside [α+β], theobromine, 7-methylurate, 3-methylxanthine, and 7-methylxanthine), a cofactor and vitamin (β-cryptoxanthin), and a lipid (chiro-inositol). In the DASH-Sodium trial, 153 and 157 urine metabolites were significantly different between the DASH high-sodium and control high-sodium diet interventions and DASH low-sodium and control high-sodium diet interventions, respectively. Importantly, 10 influential metabolites that differentiated the 2 dietary patterns were similar to the results from the DASH trial.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> These influential urine metabolites were amino acids (N-methylglutamate, N-methylproline, and N-methylhydroxyproline), xenobiotics (stachydrine, 3-hydroxystachydrine, phloroglucinol sulfate, 3,7-dimethylurate 3,5-dihydroxybenzoic acid [only for DASH high-sodium versus control high-sodium diet interventions], theobromine [only for DASH low-sodium versus control high-sodium diet interventions]), a lipid (chiro-inositol), and a carbohydrate (galactonate).</p>
            <p>Linking these candidate biomarkers of the DASH diets to reductions in BP can help identify the biological pathways contributing to the change observed. An observational study of free-living individuals related metabolomic profiling of 24-hour urine samples to adherence to the DASH diet score. These data were then used to identify pathways relating diet and BP.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> However, using self-reported diet to assess adherence to the DASH diet is subject to measurement error and recall bias.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> The present study uses the original DASH and DASH-Sodium feeding trials to identify metabolites associated with differences in SBP or DBP in response to the diet interventions.</p>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec sec-type="data-availability">
                <title>Data Availability</title>
                <p>Study data of the DASH trial and DASH-Sodium trial are available through the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center.</p>
              </sec>
              <sec>
                <title>Study Design and Study Population</title>
                <p>The DASH trial was a multisite feeding study of adults ≥22 years of age, with SBP &lt;160 mm Hg and DBP of 80 to 95 mm Hg, which aimed to test the effect of diet on BP.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> The DASH trial randomly assigned participants to the DASH diet, fruit and vegetable diet, and control diet for 8 weeks (parallel arm design). The DASH-Sodium trial was a multisite feeding study of adults ≥22 years of age, with SBP of 120 to 159 mm Hg and DBP of 80 to 95 mm Hg, which tested the combined effect of DASH diet and sodium on BP.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Similar to the DASH trial, the DASH-Sodium trial randomly assigned participants to the DASH diet and control diet interventions (parallel arm design). Within each diet intervention of the DASH-Sodium trial, participants received high, intermediate, and low sodium in random order for 4 weeks (crossover design).</p>
                <p>We used biospecimens stored in the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> For this metabolomics study, in the DASH trial (n=459), we excluded participants who did not consent to the use of their biospecimens (n=113), those who did not attend week 8 visit (n=10), those with insufficient serum volume (n=4), those whose biological specimens were not in repository (n=3), and participants who were assigned to the fruit and vegetable diet (n=111; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Figure S1</ext-link>). In the DASH-Sodium trial (n=412), we excluded participants with no biospecimen or those who did not consent to the use of their biospecimens (n=17). The final analytic sample for the DASH trial was 218 and the DASH-Sodium trial was 395.</p>
                <p>We focused on the 3 comparisons, consistent with our prior comparisons<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup>: (1) DASH versus control diet in the DASH trial (serum metabolites), (2) DASH high-sodium versus control high-sodium diet in the DASH-Sodium trial (urine metabolites), and (3) DASH low-sodium versus control high-sodium diet in the DASH-Sodium trial (urine metabolites). The last comparison was conducted to maximize the contrast between an ideal diet and typical US diet.</p>
              </sec>
              <sec>
                <title>Dietary Exposures</title>
                <p>Detailed descriptions of the DASH diets in the DASH and DASH-Sodium trials have been published.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref></sup> Briefly, the DASH diets are high in fruits, vegetables, and low-fat dairy; moderate in poultry, fish, and plant proteins (nuts and beans); and low in red and processed meats and sugar-sweetened beverages. Compared with the control diets, the DASH diets had high amounts of carbohydrate, protein, fiber, potassium, magnesium (all of which were close to the 75th percentile of US consumption), and low amounts of cholesterol and saturated fat, specifically saturated fat. The control diets were comprised of macronutrients similar to the mean of US consumption, and calcium, magnesium, and potassium were set close to the 25th percentile of US consumption. In the DASH trial, the sodium level was identical in the DASH and control diets (3000 mg/d) at the 2100-kcal level. In the DASH-Sodium trial, sodium levels differed (high-sodium phase, 3450 mg; intermediate-sodium phase, 2300 mg; low-sodium phase, 1150 mg/day) at the 2100-kcal level.</p>
                <p>Participants received prepared meals during the trial period corresponding to their diet assignment and ate lunch or dinner at onsite during weekdays. Participants received other meals to be consumed offsite. Adherence to the dietary pattern was high, as reflected by urinary excretion of urea nitrogen, potassium, and phosphorus.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup></p>
              </sec>
              <sec>
                <title>Metabolomic Profiling</title>
                <p>Global, untargeted metabolomic profiling was conducted using serum specimens collected at the end of the 8-week interventions in the DASH trial and using urine specimens collected at the end of the 4-week interventions in the DASH-Sodium trial. Biospecimens were analyzed in single batches in random order, separately for the DASH and DASH-Sodium trials. Biospecimens were not ordered by dietary interventions and were deidentified. For quality control, 20 replicate samples were included for the DASH-Sodium trial. For quality control, 20 replicate samples were included for the DASH-Sodium trial. Reproducibility of metabolite measurements was high and is reported in a previous publication.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p>
                <p>Metabolomic data were collected using 4 separate ultra-high-performance liquid chromatography tandem mass spectrometry methods. Two methods, one optimized for hydrophobic metabolites the other for hydrophilic, used reverse-phase chromatography and positive electrospray ionization. Another used reverse-phase chromatography and negative electrospray ionization, and the third used hydrophobic interaction liquid chromatography and negative ionization. All data were generated using Waters Acquity LC equipment coupled to ThermoScientific Orbitrap–based mass spectrometers (either Q-Exactive or Orbitrap Exploris). Metabolites were identified as a tier 1 or tier 2 level of certainty. Metabolites were considered a tier 1 level of certainty if at least 2 orthogonal measurements, such as accurate mass, retention time, or fragmentation patterns, matched to an authentic reference.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> Metabolites with a tier 2 level of certainty are represented with a symbol (‡) in <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Tables S1 through S6</ext-link>. Metabolites were categorized into 8 super pathways (amino acids, carbohydrates, cofactors and vitamins, energy, lipids, nucleotides, peptides, and xenobiotics) and more detailed subpathways.</p>
                <p>Details on metabolite data cleaning procedures are reported in previous publications.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> Briefly, metabolites with &gt;80% missing values were excluded. For the remaining metabolites, missing values were imputed at the minimum level detectable, rescaled to a median of 1, by dividing by the batch-specific median and log<sub>e</sub> transformed. Outliers were capped at mean ±5 SDs. For the present study, we focused on 97 serum metabolites that were significantly different between the DASH and control diet interventions in the DASH trial and 153 and 157 urine metabolites that were significantly different between the DASH high-sodium and control high-sodium diet interventions and DASH low-sodium versus control high-sodium diet interventions, respectively, in the DASH-Sodium trial.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup></p>
              </sec>
              <sec>
                <title>Blood Pressure</title>
                <p>BP measurements were obtained during screening visits, run-in visits where all participants were fed the control diets, and intervention periods where participants were randomized to DASH or control diet interventions.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> Trained staff measured participants’ SBP and DBP using a random zero sphygmomanometer using the same procedures for the DASH and DASH-Sodium trials. In both trials, 2 blood pressure measurements were obtained after a 5-minute period of sitting.</p>
                <p>Baseline measurement was defined as the average of BP measurements from screening visits (3 pairs of measurements for both trials) and run-in visits (4 pairs of measurements for the DASH and 2 pairs of measurements for the DASH-Sodium trials). End-of-trial BP was defined as the average of 4 or 5 pairs of measurements during the last 2 weeks of the intervention feeding period for the DASH trial and the final 9 days of the intervention feeding period for the DASH-Sodium trial.</p>
                <p>To calculate change in BP, we took the difference between the end-of-trial BP and baseline measurements.</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>We examined baseline characteristics of the DASH and DASH-Sodium trial participants. We examined the association between metabolites and change in BP using multivariable linear regression models and tested for interactions between diet interventions and metabolites for the 3 comparisons (main analysis): (1) DASH versus control diets in the DASH trial (97 serum metabolites), (2) DASH high-sodium versus control high-sodium diet in the DASH-Sodium trial (153 urine metabolites), and (3) DASH low-sodium versus control high-sodium diet in the DASH-Sodium trial (157 urine metabolites). Our interpretation was that differences in metabolites by diet interventions in relation to changes in BP change will help expand our understanding on the mechanisms underlying DASH diet and BP. We adjusted for the same set of covariates in our prior publications.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> In the DASH trial (serum), we adjusted for age, sex, race, education, body mass index, and hypertension. In the DASH-Sodium trial where we tested 2 comparisons (urine), we adjusted for age, sex, race, income, body mass index, and 24-hour urine creatinine. As opposed to indexing urine metabolites to creatinine, urine creatinine was adjusted as a covariate to improve interpretability of β-coefficients. We considered <italic toggle="yes">P</italic> for interaction &lt;0.05 to be statistically significant. We did not adjust for multiple testing, given that our analytic samples were small, and we used a discovery approach, focused on hypothesis generation. Further, not adjusting for multiple testing is justified in continuous by dichotomous interaction analyses when the interaction effect size is high but sample size is &lt;500.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> In our analyses, for all metabolites that were considered significant at <italic toggle="yes">P</italic> for interaction &lt;0.05, the interaction effect size was high (range of β-coefficients for the interaction terms, −4.25 to 2.80).</p>
                <p>We used scatterplots to visually describe the association between metabolites with statistically significant interactions and change in BP. Then, pathway overrepresentation analysis was constructed for metabolites with significant interactions for the association between diet interventions and SBP or DBP, separately for the DASH trial (serum) and DASH-Sodium trial (urine), using subpathway classification of metabolites.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p>
                <p>As a secondary analysis, we performed elastic net linear regression to identify a combination of metabolites that predict changes in BP. We conducted 3 analyses, similar to the main analyses: (1) DASH versus control diets in the DASH trial (97 serum metabolites), (2) DASH high-sodium versus control high-sodium diet in the DASH-Sodium trial (153 urine metabolites), and (3) DASH low-sodium versus control high-sodium diet in the DASH-Sodium trial (157 urine metabolites).</p>
                <p>As an exploratory analysis, we used multivariable linear regression models and tested for interactions between diet interventions and significant metabolites separately for men and women. We examined relationships between significant metabolites by constructing correlation matrices in the DASH and DASH-Sodium trials. As sensitivity analyses, in both trials, we adjusted for (1) change in BMI and (2) baseline BP.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <p>The characteristics of DASH and DASH-Sodium trial participants at baseline were generally similar, by percentage of Black people, education, total energy intake, body mass index, weight, and 24-hour urine creatinine (Table <xref rid="T1" ref-type="table">1</xref>). The proportion of participants who were &gt;30 years, those who are women, income ≥$60 000, current smokers, and those who were hypertensive was slightly higher in the DASH-Sodium trial. SBP and DBP was higher for participants in the DASH-Sodium trial than the DASH trial.</p>
              <table-wrap position="float" id="T1">
                <label>Table 1.</label>
                <caption>
                  <p>Baseline Participant Characteristics in the DASH and the DASH-Sodium Trials*</p>
                </caption>
                <graphic xlink:href="hyp-80-1494-g001" position="float"/>
              </table-wrap>
              <p>We identified 65 significant interactions by metabolites (DASH trial [serum], 12; DASH high sodium [urine], 35; DASH low sodium [urine], 18; Figures <xref rid="F1" ref-type="fig">1</xref> through <xref rid="F3" ref-type="fig">3</xref>; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Tables S1 and S2</ext-link>) for the association between diet and change in BP. Of the 65 interactions, 42 unique metabolites (9 serum metabolites and 33 urine metabolites) were associated with either SBP or DBP.</p>
              <fig position="float" id="F1">
                <label>Figure 1.</label>
                <caption>
                  <p><bold>Associations between Dietary Approaches to Stop Hypertension (DASH) diet–related serum metabolites and systolic or diastolic blood pressure in the DASH trial.</bold> β coefficients and 95% CIs were calculated using multivariable linear regression models for 1 SD higher in metabolite, adjusting for age, sex, race, education, body mass index, and hypertension. Only metabolites with significant interaction with diet interventions (<italic toggle="yes">P</italic> for interaction, &lt;0.05) are presented. *Metabolites with a tier 2 certainty, which were not confirmed by a reference standard.</p>
                </caption>
                <graphic xlink:href="hyp-80-1494-g002" position="float"/>
              </fig>
              <fig position="float" id="F2">
                <label>Figure 2.</label>
                <caption>
                  <p><bold>Associations between Dietary Approaches to Stop Hypertension (DASH) diet–related urine metabolites and systolic or diastolic blood pressure in the DASH-Sodium trial.</bold> We compared DASH high-sodium diet and control high-sodium diet interventions. β coefficients and 95% CIs were calculated using multivariable linear regression models for 1 SD higher in metabolite, adjusting for age, sex, race, income, body mass index, and 24-hour urine creatinine. Only metabolites with significant interaction with diet interventions (<italic toggle="yes">P</italic> for interaction, &lt;0.05) are presented. CEHC indicates carboxyethylhydroxychroman. *Metabolites with a tier 2 certainty, which were not confirmed by a reference standard.</p>
                </caption>
                <graphic xlink:href="hyp-80-1494-g003" position="float"/>
              </fig>
              <fig position="float" id="F3">
                <label>Figure 3.</label>
                <caption>
                  <p><bold>Scatterplots of Dietary Approaches to Stop Hypertension (DASH) diet–related metabolites and systolic blood pressure (SBP) or diastolic blood pressure (DBP). A</bold>, Serum tryptophan betaine in the DASH and control diet interventions in the DASH trial. <bold>B</bold>, Urine stachydrine in the DASH high-sodium compared with control high-sodium diet interventions in the DASH-Sodium trial. <bold>C</bold>, Urine N-methylglutamate in the DASH low-sodium compared with control high-sodium diet interventions in the DASH-Sodium trial. Blue line represents linear regression line, and gray shaded area represents 95% CIs.</p>
                </caption>
                <graphic xlink:href="hyp-80-1494-g004" position="float"/>
              </fig>
              <p>In the DASH trial (serum), all lipid metabolites (10 of 10) were lower in participants consuming the DASH diet compared with control diet. These lipid metabolites (ceramides and phosphatidylcholines) were associated with BP elevations in participants consuming the DASH diet and reductions in BP in participants consuming the control diet (<italic toggle="yes">P</italic> for interaction for all tests, &lt;0.05; Figure <xref rid="F1" ref-type="fig">1</xref>; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Table S1</ext-link>). Serum ceramides such as N-palmitoyl-sphingosine (d18:1/16:0) were lower in response to the DASH diet compared with the control diet, as well as elevations in SBP and DBP. In contrast, N-palmitoyl-sphingosine (d18:1/16:0) was associated with reductions in SBP and DBP in response to the control diet (<italic toggle="yes">P</italic> for interaction for both tests, &lt;0.05; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Figure S2A</ext-link>). A cofactor and vitamin (1 of 1) and an amino acid (1 of 1) were higher after the participants consumed the DASH diets compared with the control diets. Serum tryptophan betaine, an amino acid, was higher in individuals consuming the DASH versus control diet. Levels of tryptophan betaine at the end of diet interventions were different by diet interventions in relation to changes in BP (Figure <xref rid="F3" ref-type="fig">3</xref>A). Tryptophan betaine was significantly associated with reductions in DBP in response to the DASH diet but not the control diet (<italic toggle="yes">P</italic> for interaction, 0.023).</p>
              <p>In the DASH high sodium (urine), all cofactors and vitamins (9 of 9), peptides (3 of 3), nucleotides (1 of 1), most amino acids (9 of 10), and xenobiotics (6 of 10) were higher after the participants consumed the DASH diet compared with the control diet. Distributions of these metabolites differed by diet interventions in relation to changes in BP. In general, these metabolites were associated with SBP or DBP reductions in participants consuming the DASH diet and elevations in BP in participants consuming the control diet (<italic toggle="yes">P</italic> for interaction for all tests, &lt;0.05). N-methylproline (an amino acid), stachydrine (a xenobiotic), and thiamin (a cofactor and vitamin) were higher in the DASH high-sodium compared with control high-sodium diet. N-methylproline was associated with reductions in DBP in response to the DASH diet and not significantly associated with DBP in response to the control diet (<italic toggle="yes">P</italic> for interaction, 0.03) (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Table S2</ext-link>; Figure <xref rid="F2" ref-type="fig">2</xref>). Similar associations were observed for stachydrine and thiamin for SBP (<italic toggle="yes">P</italic> for interaction for all tests, &lt;0.05; Figure <xref rid="F3" ref-type="fig">3</xref>B; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Figure S2B</ext-link>).</p>
              <p>In the DASH low sodium (urine), amino acids (n=8), and cofactors and vitamins (n=5) were the most common categories of metabolites that were associated with BP differently by diet intervention (Figure <xref rid="F4" ref-type="fig">4</xref>; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Table S2</ext-link>). Urine N-methylglutamate and N-methylhydroxyproline (amino acids) were higher in individuals consuming the DASH low-sodium diet compared with individuals consuming the control high-sodium diet. N-methylglutamate and N-methylhydroxyproline were associated with significant reductions in SBP in response to the DASH but not control diet (<italic toggle="yes">P</italic> for interaction for both metabolites, &lt;0.05; Figure <xref rid="F3" ref-type="fig">3</xref>C; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Figure S2C</ext-link>).</p>
              <fig position="float" id="F4">
                <label>Figure 4.</label>
                <caption>
                  <p><bold>Associations between Dietary Approaches to Stop Hypertension (DASH) diet–related urine metabolites and systolic or diastolic blood pressure in the DASH-Sodium trial.</bold> We compared DASH low-sodium diet and control high-sodium diet interventions. β coefficients and 95% CIs were calculated using multivariable linear regression models for 1 SD higher in metabolite, adjusting for age, sex, race, income, body mass index, and 24-hour urine creatinine. Only metabolites with significant interaction with diet interventions (<italic toggle="yes">P</italic> for interaction, &lt;0.05) are presented. CEHC indicates carboxyethylhydroxychroman. *Metabolites with a tier 2 certainty, which were not confirmed by a reference standard.</p>
                </caption>
                <graphic xlink:href="hyp-80-1494-g005" position="float"/>
              </fig>
              <p>The direction of association was unexpected for 4 metabolites (carotene diol, N-carbamoylvaline, 3-hydroxyindolin-2-one, and 4-hydroxycinnamate). In the DASH trial (serum), levels of carotene diol were higher in response to the DASH compared with control diet, thus we expected that carotene diol would be associated with reductions in BP in individuals consuming the DASH diet. However, carotene diol was significantly associated with elevations in SBP in the DASH diet intervention (<italic toggle="yes">P</italic> for interaction, 0.016). Similarly, in DASH high sodium (urine), N-carbamoylvaline, 3-hydroxyindolin-2-one, and 4-hydroxycinnamate, were lower in response to the DASH high-sodium compared with the control high-sodium diet. We would have expected these 3 metabolites to be associated with elevations in BP in individuals consuming the DASH high-sodium diet. However, 3 metabolites were associated with significant reductions in SBP or DBP in the DASH high-sodium diet (<italic toggle="yes">P</italic> for interactions for all tests, &lt;0.05).</p>
              <p>We found that metabolites involved in 7 pathways were overrepresented in serum or urine samples (Table <xref rid="T2" ref-type="table">2</xref>). In the DASH trial (serum), metabolites in the ceramide and phosphatidylcholine pathways were overrepresented. In the DASH-Sodium trial (urine), metabolites in the tocopherol metabolism, pantothenate and coenzyme A metabolism, tyrosine metabolism, acetylated peptides, and thiamine metabolism were overrepresented.</p>
              <table-wrap position="float" id="T2">
                <label>Table 2.</label>
                <caption>
                  <p>Pathway Overrepresentation Analysis of DASH Diet–Related Metabolites Significantly Associated With SBP or DBP for the DASH Trial and DASH-Sodium Trial*</p>
                </caption>
                <graphic xlink:href="hyp-80-1494-g006" position="float"/>
              </table-wrap>
              <p>In elastic net models, fewer metabolites were associated with BP reduction than the main analysis. Some metabolites identified using elastic net models overlapped with the findings from our main analysis. In the DASH trial, we identified 6 serum metabolites (tryptophan betaine, β-cryptoxanthin, 1-oleoyl-GPC [18:1], 1-stearoyl-2-oleoyl-GPC [18:0/18:1], 1-[1-enyl-stearoyl]-2-linoleoyl-GPE [P-18:0/18:2], and theobromine) that represented changes in SBP (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Table S3</ext-link>). Serum tryptophan betaine and β-cryptoxanthin were associated with reduction in SBP, and the remaining 4 metabolites were associated with elevations in SBP. In the DASH-Sodium trial, results were similar for the DASH high-sodium and control high-sodium phases and DASH low-sodium and control high-sodium phases (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Table S4</ext-link>). Five metabolites (theobromine, 3-methylxanthine, 3,5-dihydroxybenzoic acid, N-methylglutamate, and stachydrine) represented changes in BP in the 2 analyses conducted in the DASH-Sodium trial. Of these, 3,5-dihydroxybenzoic acid, N-methylglutamate, and stachydrine were associated with reductions in BP, and theobromine and 3-methylxanthine were associated with elevations in BP.</p>
              <p>In sex-stratified analyses, the direction of association was generally consistent for women and men in the DASH diet intervention, and statistical evidence of interaction was present for a few metabolites, despite the small sample size and lower statistical power (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Tables S5 and S6</ext-link>).</p>
              <p>As expected, serum lipids were positively correlated with each other and negatively associated with tryptophan betaine in the DASH trial (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Figure S3A</ext-link>). Urine cofactors and vitamins were correlated with each other and some amino acids in the DASH-Sodium trial (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">Figure S3B</ext-link>).</p>
              <p>In a sensitivity analysis, additionally adjusting for change in BMI did not change the results for most metabolites in the DASH and DASH-Sodium trials, except for the association between N-palmitoyl-sphingosine (d18:1/16:0) and change in DBP in the control diet. The results did not meaningfully change when we additionally adjusted for baseline BP.</p>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>Using data from 2 randomized controlled feeding trials, we identified 42 DASH diet–related metabolites (9 serum metabolites and 33 urine metabolites) that had different associations with changes in SBP and DBP for the DASH versus control interventions. Serum tryptophan betaine (amino acid) was associated with a greater reduction in DBP in individuals consuming the DASH diet and not in individuals consuming the control diet. Serum ceramides and phosphatidylcholines were associated with elevations in SBP or DBP in individuals provided with the DASH diet and with reductions in SBP or DBP in individuals provided with the control diet. Urine cofactors and vitamins, peptides, nucleotides, amino acids, and xenobiotics were associated with SBP or DBP reductions in participants consuming the DASH diet and with elevations in BP in participants consuming the control diet. Compared with the analysis on individual metabolites, elastic net models identified fewer metabolites. Metabolites involved in 7 pathways were overrepresented. Our results suggest these metabolic pathways that are relevant for DASH diet–blood pressure associations.</p>
              <p>From the main analysis and elastic net models, serum tryptophan betaine (associated with SBP or DBP) and urine N-methylglutamate (associated with SBP) in the DASH and DASH-Sodium trials, respectively, were among the top 10 metabolites, which distinguished DASH diets and control diets.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> Tryptophan betaine (or hypaphorine)—a biomarker of legume intake—has been shown to reduce endothelial inflammation in vitro.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> N-methylglutamate has been linked to intake of fruits.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> N-methylglutamate is a derivative of glutamic acid, an amino acid that is found in dietary protein and especially plant protein.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> Intake of glutamic acids was higher in individuals consuming high plant protein and low animal protein, and dietary intake of glutamic acids has been linked to lower BP in observational studies.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> Glutamic acid is a substrate for glutathione production, which has been reported to reduce oxidative injury and improve availability of a vasodilator (NO).<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Considering that urine levels of N-methylglutamate were significantly different only in the DASH low-sodium versus control high-sodium interventions, N-methylglutamate may also be related to low sodium intake. However, no previous studies have reported a link between this metabolite and dietary sodium. Nonetheless, our findings suggest glutathione metabolism is an important pathway through which DASH diet reduces BP.</p>
              <p>In the DASH-Sodium trial, urine levels of stachydrine (also known as proline betaine), 3-hydroxystachydrine, N-methylproline, and N-methylhydroxyproline were significantly associated with reductions in SBP or DBP in individuals consuming a DASH diet but not a control diet. Urine stachydrine was also selected from elastic net models. All of these metabolites are proline derivatives that have been linked to citrus fruit intake.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> Proline is thought to protect against redox imbalance and serve as an antioxidant agent, by scavenging reactive oxygen species, upregulating and stabilizing antioxidant enzymes, and chelating metals.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Further, proline has been suggested to increase the production of NO, given that proline may be a precursor of arginine synthesis.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> In rats with angiotensin II–induced hypertension, proline supplementation reduced SBP, increased biomarkers related to NO (urinary nitrates and urinary nitrites), and lowered plasma asymmetric dimethylarginine (contributor of oxidative stress and endothelial dysfunction).<sup><xref rid="R31" ref-type="bibr">31</xref></sup> In addition, our findings are consistent with a previous study of DASH diet high in carbohydrate, which reported an inverse association between urinary stachydrine and SBP and DBP.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></p>
              <p>Other metabolites (serum β-cryptoxanthin and theobromine from the DASH trial; urine 3,5-dihydroxybenzoic acid, theobromine, and 3-methylxanthine from the DASH-Sodium trial) identified from elastic net models have been linked to BP. In the DASH trial, serum β-cryptoxanthin was higher in individuals consuming the DASH versus control diet. β-Cryptoxanthin is a carotenoid (well-known antioxidant) found in fruits and vegetables.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Consistent with our observation, serum β-cryptoxanthin has been negatively correlated with SBP in a nationally representative sample of US adults.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> In the DASH-Sodium trial, urine 3,5-dihydroxybenzoic acid was higher in individuals consuming the DASH versus control diet, and urine levels of theobromine and 3-methylxanthine were lower in individuals consuming the DASH versus control diet. Urine 3,5-dihydroxybenzoic acid has been proposed as a biomarker of whole grain intake.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> A tripeptide (Leu-Arg-Ala) found in rice bran protein was reported to have vasorelaxant activity by producing NO.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Urine theobromine and methylxanthines are metabolites of caffeine intake.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> There is mixed evidence on habitual caffeine intake and BP, but, in a review of clinical trials, caffeine intake led to an acute increase in BP in hypertensive individuals.<sup><xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R38" ref-type="bibr">38</xref></sup></p>
              <p>Several pathways were overrepresented in our analysis. Urine metabolites involved in tocopherol metabolism (fruits and green leafy vegetables), tyrosine metabolism (nuts and legumes and low-fat dairy), and thiamine metabolism (fish, seeds, and grains) reflect the food composition of the DASH diet. Of these, urine α-carboxyethylhydroxychroman in the tocopherol metabolism pathway has been proposed as a biomarker of vitamin E intake and is a well-known antioxidant.<sup><xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R40" ref-type="bibr">40</xref></sup> Thiamine was associated with reductions in SBP and DBP in the DASH diet intervention but not in the control diet intervention in the DASH-Sodium trial. Thiamine serves as a coenzyme for the conversion of pyruvate to acetyl-CoA.<sup><xref rid="R41" ref-type="bibr">41</xref></sup> Thiamine repletion in spontaneous hypertensive rats reduced SBP, accompanied by correcting for glucose shunting into the hexoamine biosynthetic pathway at its cellular entry.<sup><xref rid="R42" ref-type="bibr">42</xref></sup> In this rat model, thiamine repletion downregulated mRNA levels encoding the renin-angiotensin system in epididymal adipose tissue, highlighting the role that thiamine plays in BP reduction.</p>
              <p>In the DASH-Sodium trial, urine metabolites related to pantothenate and CoA metabolism were overrepresented. Urine levels of pantothenate were higher among individuals randomly assigned to the DASH diet intervention compared with those assigned to the control diet intervention, and this metabolite was associated with a reduction in SBP and DBP in individuals on the DASH diet. Pantothenate is a component of coenzyme A, which acts as a cofactor in many biochemical reactions.<sup><xref rid="R43" ref-type="bibr">43</xref></sup> Acetyl-CoA is utilized for acetylcholine synthesis, which leads to activation of endothelial muscarinic receptors. This process can stimulate the release of NO, resulting in vasorelaxation.<sup><xref rid="R44" ref-type="bibr">44</xref>,<xref rid="R45" ref-type="bibr">45</xref></sup> Low levels of urine pantothenate have also been linked to diabetic kidney disease and CVD risk factors (metabolic syndrome, hyperglycemia, hypertension, or albuminuria).<sup><xref rid="R46" ref-type="bibr">46</xref></sup></p>
              <p>In the DASH trial, serum ceramides were significantly lower in individuals on the DASH versus control diets after 8 weeks of a controlled feeding period. Ceramides are sphingolipids, which are known to have adverse effects on blood vessels.<sup><xref rid="R47" ref-type="bibr">47</xref></sup> Higher levels of circulating ceramides were associated with incident CVD, heart failure, diabetes, and premature death.<sup><xref rid="R48" ref-type="bibr">48</xref>–<xref rid="R50" ref-type="bibr">50</xref></sup> In the PREDIMED trial (Prevención con Dieta Mediterránea), a baseline ceramide score (weighted sum of C16:0, C22:0, C24:0, and C24:1) was associated with higher risk of incident CVD.<sup><xref rid="R51" ref-type="bibr">51</xref></sup> However, individuals with a high ceramide score and assigned to Mediterranean diet interventions had a similar risk of CVD to those with a low ceramide score. Those with a high ceramide score and assigned to the control diet intervention had elevated risk of incident CVD. The PREDIMED trial observed that Mediterranean diet interventions did not alter plasma ceramides at 1 year of follow-up. Our results are not directly comparable to the PREDIMED trial due to differences in outcomes (change in BP versus a hard, clinical end point), duration of diet (4–8 weeks versus 1 year), and ceramides (prior study has information on only the number of carbons and double bonds).</p>
              <p>Our study design is a major strength. We used metabolomics data derived from rigorously conducted and well-characterized controlled feeding studies, which maintained participants’ weight stable throughout the study period. Participants were randomly assigned to dietary interventions, which is expected to distribute known and unknown confounders equally. Participants were provided all meals, compliance to the dietary patterns was high, and BP was measured according to standardized protocols. Thus, our results improve upon the prior study of self-reported diet.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Our metabolomic platform identified metabolites with short half-lives (eg, polyphenols), which allows us to attribute metabolites of BP changes to the diet interventions despite them being administered over a relatively short period of time (ie, 4 or 8 weeks).<sup><xref rid="R52" ref-type="bibr">52</xref></sup> Approximately half of the study participants in the DASH and DASH-Sodium trials were women or Black people, and direction of associations was generally consistent for women and men assigned to the DASH diet. We utilized serum and urine specimens in 2 different trials. Theobromine and a few other metabolites (stachydrine and tryptophan betaine) were present in both serum and urine, but many metabolites did not overlap across the 2 specimen types. Detectability of metabolites in biofluids may be influenced by multiple factors (eg, site of gut absorption, lipid solubility, and half-life).<sup><xref rid="R20" ref-type="bibr">20</xref></sup> However, both serum and urine may provide useful information. Serum metabolites are homeostatically regulated, whereas urine metabolites reflect excreted metabolites that have been degraded. It has been reported that more urine metabolites were uniquely associated with diet than in serum.<sup><xref rid="R53" ref-type="bibr">53</xref></sup> Serum may be considered more invasive to collect than urine, but it is also burdensome for participants to collect urine specimens over a 24-hour period (as used in the DASH-Sodium trial). For future research, it may be informative to assess both specimen types in the same population and in the context of food metabolism, recognizing the advantages and disadvantages of 2 specimen types.</p>
              <p>Limitations of the study include modest sample size, which might have limited the ability to detect significant statistical interactions. To address this limitation, we used 0.05 to define the statistical threshold for interactions. Despite the nonstringent threshold, it is encouraging that the direction of association between the metabolite and BP differed for the DASH versus control diet interventions. The diet interventions lasted for 8 and 4 weeks for the DASH and DASH-Sodium trials, respectively. However, many metabolites representative of the DASH diet were replicated in independent study populations with data on usual dietary intake.<sup><xref rid="R54" ref-type="bibr">54</xref>–<xref rid="R56" ref-type="bibr">56</xref></sup> Biospecimens used for metabolomic profiling were in storage for &gt;20 years. Metabolites may have degraded over time, but it would be nondifferential by DASH and control diet interventions. One study reported that only 2% of blood metabolites were altered after being stored for 7 years and 26% of blood metabolites were altered with longer storage periods (up to 16 years).<sup><xref rid="R57" ref-type="bibr">57</xref></sup> In urine, values of half of the analytes were not significantly different after &gt;10 years of storage.<sup><xref rid="R58" ref-type="bibr">58</xref></sup> Our results should be comparable to analyses of trials with shorter storage of biospecimens. We did not have baseline assessment of metabolites, which would have provided more information on change in metabolites and corresponding changes in BP. Future research may consider longitudinal change in metabolites to examine potential mechanisms through which DASH diet is associated with BP lowering.</p>
            </sec>
            <sec>
              <title>Perspectives</title>
              <p>We identified 42 unique metabolites (9 serum and 33 urine) that significantly associated with changes in SBP or DBP DASH versus control diet interventions in 2 randomized feeding studies. Of the 42 metabolites, several metabolites (serum tryptophan betaine, urine N-methylglutamate, urine proline derivatives such as stachydrine, 3-hydroxystachydrine, N-methylproline, and N-methylhydroxyproline) that were influential in distinguishing between the DASH diet and control diet interventions were associated with reductions in SBP or DBP in the DASH diet intervention but not in the control diet intervention. Pathway overrepresentation analysis revealed metabolite pathways (eg, tocopherol metabolism, tyrosine metabolism, thiamine metabolism, pantothenate and coenzyme A metabolism, and ceramides) that were relevant for the association between DASH diet and BP. Our findings highlight metabolites and metabolic pathways that are modifiable by DASH diet consumption. These results provide insights on formulating intervention strategies to reduce BP.</p>
            </sec>
            <sec>
              <title>Article Information</title>
              <sec>
                <title>Acknowledgments</title>
                <p>The authors thank the participants of the DASH (Dietary Approaches to Stop Hypertension) and DASH-Sodium trials for their important contributions.</p>
              </sec>
              <sec>
                <title>Author Contributions</title>
                <p>H. Kim wrote the manuscript and analyzed the data. H. Kim had the primary responsibility for the final content. L.J. Appel, A.H. Lichtenstein, K.E. Wong, N. Chatterjee, and E.P. Rhee contributed to manuscript revision and gave critical suggestions for the development of this article. C.M. Rebholz was involved in all aspects of the study, from study design to analysis to manuscript writing. All authors approved the manuscript.</p>
              </sec>
              <sec>
                <title>Sources of Funding</title>
                <p>This research was supported by the National Heart, Lung, and Blood Institute (NHLBI; R01 HL153178). H. Kim was supported by a grant from the NHLBI (K01 HL168232). C.M. Rebholz was additionally supported by a grant from the National Institute of Diabetes and Digestive and Kidney Disease (R03 DK128386).</p>
              </sec>
              <sec sec-type="COI-statement">
                <title>Disclosures</title>
                <p>None.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <media id="s1" content-type="document" xlink:href="hyp-80-1494-s001.pdf" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="abbr">
                <p>
                  <def-list>
                    <title>Nonstandard Abbreviations and Acronyms</title>
                    <def-item>
                      <term>BP</term>
                      <def>
                        <p>blood pressure</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>CVD</term>
                      <def>
                        <p>cardiovascular disease</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>DASH</term>
                      <def>
                        <p>Dietary Approaches to Stop Hypertension</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>DBP</term>
                      <def>
                        <p>diastolic blood pressure</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>PREDIMED</term>
                      <def>
                        <p>Prevención con Dieta Mediterránea</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>SBP</term>
                      <def>
                        <p>systolic blood pressure</p>
                      </def>
                    </def-item>
                  </def-list>
                </p>
              </fn>
            </fn-group>
            <fn-group>
              <fn fn-type="financial-disclosure">
                <p>For Sources of Funding and Disclosures, see page 1505.</p>
              </fn>
              <fn fn-type="supplementary-material">
                <p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.20901</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Vadiveloo</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Kris-Etherton</surname><given-names>PM</given-names></name><name><surname>Rebholz</surname><given-names>CM</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Thorndike</surname><given-names>AN</given-names></name><name><surname>Van Horn</surname><given-names>L</given-names></name><name><surname>Wylie-Rosett</surname><given-names>J</given-names></name></person-group>. <article-title>2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association.</article-title><source>Circulation</source>. <year>2021</year>;<volume>144</volume>:<fpage>e472</fpage>–<lpage>e487</lpage>. <comment>doi: 10.1161/CIR.0000000000001031</comment><pub-id pub-id-type="pmid">34724806</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="book"><collab>US Department of Agriculture, US Department of Health and Human Services, Health and Human Services</collab>. <source>Dietary Guidelines for Americans, 2020-2025 [Internet]</source>. <publisher-name>US Government Printing Office</publisher-name>; <year>2020</year>. <comment><ext-link xlink:href="https://www.dietaryguidelines.gov/" ext-link-type="uri">https://www.dietaryguidelines.gov/</ext-link></comment></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Moore</surname><given-names>TJ</given-names></name><name><surname>Obarzanek</surname><given-names>E</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><name><surname>Svetkey</surname><given-names>LP</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>Vogt</surname><given-names>TM</given-names></name><name><surname>Cutler</surname><given-names>JA</given-names></name><name><surname>Windhauser</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>A clinical trial of the effects of dietary patterns on blood pressure.</article-title><source>N Engl J Med</source>. <year>1997</year>;<volume>336</volume>:<fpage>1117</fpage>–<lpage>1124</lpage>. <comment>doi: 10.1056/nejm199704173361601</comment><pub-id pub-id-type="pmid">9099655</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Svetkey</surname><given-names>LP</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>Harsha</surname><given-names>D</given-names></name><name><surname>Obarzanek</surname><given-names>E</given-names></name><name><surname>Conlin</surname><given-names>PR</given-names></name><name><surname>Miller</surname><given-names>ER</given-names></name><name><surname>Simons-Morton</surname><given-names>DG</given-names></name><etal/></person-group>; <collab>DASH-Sodium Collaborative Research Group</collab>. <article-title>Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet.</article-title><source>N Engl J Med</source>. <year>2001</year>;<volume>344</volume>:<fpage>3</fpage>–<lpage>10</lpage>. <comment>doi: 10.1056/NEJM200101043440101</comment><pub-id pub-id-type="pmid">11136953</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebholz</surname><given-names>CM</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name></person-group>. <article-title>Serum untargeted metabolomic profile of the Dietary Approaches to Stop Hypertension (DASH) dietary pattern.</article-title><source>Am J Clin Nutr</source>. <year>2018</year>;<volume>108</volume>:<fpage>243</fpage>–<lpage>255</lpage>. <comment>doi: 10.1093/ajcn/nqy099</comment><pub-id pub-id-type="pmid">29917038</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>Wong</surname><given-names>KE</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Rebholz</surname><given-names>CM</given-names></name></person-group>. <article-title>Urine metabolites associated with the Dietary Approaches to Stop Hypertension (DASH) diet: results from the DASH-Sodium trial.</article-title><source>Mol Nutr Food Res</source>. <year>2020</year>;<volume>65</volume>:<fpage>e2000695</fpage>. <comment>doi: 10.1002/mnfr.202000695</comment><pub-id pub-id-type="pmid">33300290</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>Q</given-names></name><name><surname>Wren</surname><given-names>GM</given-names></name><name><surname>Lau</surname><given-names>C-HE</given-names></name><name><surname>Ebbels</surname><given-names>TMD</given-names></name><name><surname>Gibson</surname><given-names>R</given-names></name><name><surname>Loo</surname><given-names>RL</given-names></name><name><surname>Aljuraiban</surname><given-names>GS</given-names></name><name><surname>Posma</surname><given-names>JM</given-names></name><name><surname>Dyer</surname><given-names>AR</given-names></name><name><surname>Steffen</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Blood pressure interactions with the DASH dietary pattern, sodium, and potassium: the international study of macro-/micronutrients and blood pressure (INTERMAP).</article-title><source>Am J Clin Nutr</source>. <year>2022</year>;<volume>116</volume>:<fpage>216</fpage>–<lpage>229</lpage>. <comment>doi: 10.1093/ajcn/nqac067</comment><pub-id pub-id-type="pmid">35285859</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kipnis</surname><given-names>V</given-names></name><name><surname>Midthune</surname><given-names>D</given-names></name><name><surname>Freedman</surname><given-names>L</given-names></name><name><surname>Bingham</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>NE</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Carroll</surname><given-names>RJ</given-names></name></person-group>. <article-title>Bias in dietary-report instruments and its implications for nutritional epidemiology.</article-title><source>Public Health Nutr</source>. <year>2002</year>;<volume>5</volume>:<fpage>915</fpage>–<lpage>923</lpage>. <comment>doi: 10.1079/PHN2002383</comment><pub-id pub-id-type="pmid">12633516</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>LS</given-names></name><name><surname>Schatzkin</surname><given-names>A</given-names></name><name><surname>Midthune</surname><given-names>D</given-names></name><name><surname>Kipnis</surname><given-names>V</given-names></name></person-group>. <article-title>Dealing with dietary measurement error in nutritional cohort studies.</article-title><source>J Natl Cancer Inst</source>. <year>2011</year>;<volume>103</volume>:<fpage>1086</fpage>–<lpage>1092</lpage>. <comment>doi: 10.1093/jnci/djr189</comment><pub-id pub-id-type="pmid">21653922</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Obarzanek</surname><given-names>E</given-names></name><name><surname>Windhauser</surname><given-names>MM</given-names></name><name><surname>Svetkey</surname><given-names>LP</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><name><surname>McCullough</surname><given-names>M</given-names></name><name><surname>Karanja</surname><given-names>N</given-names></name><name><surname>Lin</surname><given-names>PH</given-names></name><name><surname>Steele</surname><given-names>P</given-names></name><name><surname>Proschan</surname><given-names>MA</given-names></name></person-group>. <article-title>Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A multicenter controlled-feeding study of dietary patterns to lower blood pressure.</article-title><source>Ann Epidemiol</source>. <year>1995</year>;<volume>5</volume>:<fpage>108</fpage>–<lpage>118</lpage>. <comment>doi: 10.1016/1047-2797(94)00055-x</comment><pub-id pub-id-type="pmid">7795829</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svetkey</surname><given-names>LP</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Obarzanek</surname><given-names>E</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Lin</surname><given-names>PH</given-names></name><name><surname>Karanja</surname><given-names>NM</given-names></name><name><surname>Harsha</surname><given-names>DW</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>Aickin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The DASH diet, sodium intake and blood pressure trial (DASH-Sodium): rationale and design. DASH-Sodium Collaborative Research Group.</article-title><source>J Am Diet Assoc</source>. <year>1999</year>;<volume>99</volume>:<fpage>S96</fpage>–<lpage>104</lpage>. <comment>doi: 10.1016/s0002-8223(99)00423-x</comment><pub-id pub-id-type="pmid">10450301</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giffen</surname><given-names>CA</given-names></name><name><surname>Carroll</surname><given-names>LE</given-names></name><name><surname>Adams</surname><given-names>JT</given-names></name><name><surname>Brennan</surname><given-names>SP</given-names></name><name><surname>Coady</surname><given-names>SA</given-names></name><name><surname>Wagner</surname><given-names>EL</given-names></name></person-group>. <article-title>Providing contemporary access to historical biospecimen collections: development of the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).</article-title><source>Biopreserv Biobank</source>. <year>2015</year>;<volume>13</volume>:<fpage>271</fpage>–<lpage>279</lpage>. <comment>doi: 10.1089/bio.2014.0050</comment><pub-id pub-id-type="pmid">26186276</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumner</surname><given-names>LW</given-names></name><name><surname>Amberg</surname><given-names>A</given-names></name><name><surname>Barrett</surname><given-names>D</given-names></name><name><surname>Beale</surname><given-names>MH</given-names></name><name><surname>Beger</surname><given-names>R</given-names></name><name><surname>Daykin</surname><given-names>CA</given-names></name><name><surname>Fan</surname><given-names>TW-M</given-names></name><name><surname>Fiehn</surname><given-names>O</given-names></name><name><surname>Goodacre</surname><given-names>R</given-names></name><name><surname>Griffin</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI).</article-title><source>Metabolomics</source>. <year>2007</year>;<volume>3</volume>:<fpage>211</fpage>–<lpage>221</lpage>. <comment>doi: 10.1007/s11306-007-0082-2</comment><pub-id pub-id-type="pmid">24039616</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrimpe-Rutledge</surname><given-names>AC</given-names></name><name><surname>Codreanu</surname><given-names>SG</given-names></name><name><surname>Sherrod</surname><given-names>SD</given-names></name><name><surname>McLean</surname><given-names>JA</given-names></name></person-group>. <article-title>Untargeted metabolomics strategies – challenges and emerging directions.</article-title><source>J Am Soc Mass Spectrom</source>. <year>2016</year>;<volume>27</volume>:<fpage>1897</fpage>–<lpage>1905</lpage>. <comment>doi: 10.1007/s13361-016-1469-y</comment><pub-id pub-id-type="pmid">27624161</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>CP</given-names></name></person-group>. <article-title>Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study.</article-title><source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e71079</fpage>. <comment>doi: 10.1371/journal.pone.0071079</comment><pub-id pub-id-type="pmid">23976980</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T-M</given-names></name><name><surname>Shafi</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name></person-group>. <article-title>Identifying significantly impacted pathways: a comprehensive review and assessment.</article-title><source>Genome Biol</source>. <year>2019</year>;<volume>20</volume>:<fpage>203</fpage>. <comment>doi: 10.1186/s13059-019-1790-4</comment><pub-id pub-id-type="pmid">31597578</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name></person-group>. <article-title>Hypaphorine attenuates lipopolysaccharide-Induced endothelial inflammation via regulation of TLR4 and PPAR-γ dependent on PI3K/Akt/mTOR signal pathway.</article-title><source>Int J Mol Sci</source>. <year>2017</year>;<volume>18</volume>:<fpage>E844</fpage>. <comment>doi: 10.3390/ijms18040844</comment></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name></person-group>. <article-title>Vaccaria hypaphorine alleviates lipopolysaccharide-induced inflammation via inactivation of NFκB and ERK pathways in Raw 264.7 cells.</article-title><source>BMC Complement Altern Med</source>. <year>2017</year>;<volume>17</volume>:<fpage>120</fpage>. <comment>doi: 10.1186/s12906-017-1635-1</comment><pub-id pub-id-type="pmid">28219355</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hodge</surname><given-names>RA</given-names></name><name><surname>Stevens</surname><given-names>VL</given-names></name><name><surname>Hartman</surname><given-names>TJ</given-names></name><name><surname>McCullough</surname><given-names>ML</given-names></name></person-group>. <article-title>Identification and reproducibility of urinary metabolomic biomarkers of habitual food intake in a cross-sectional analysis of the cancer prevention study-3 diet assessment sub-study.</article-title><source>Metabolites</source>. <year>2021</year>;<volume>11</volume>:<fpage>248</fpage>. <comment>doi: 10.3390/metabo11040248</comment><pub-id pub-id-type="pmid">33920694</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Playdon</surname><given-names>MC</given-names></name><name><surname>Sampson</surname><given-names>JN</given-names></name><name><surname>Cross</surname><given-names>AJ</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Guertin</surname><given-names>KA</given-names></name><name><surname>Moy</surname><given-names>KA</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Irwin</surname><given-names>ML</given-names></name><name><surname>Mayne</surname><given-names>ST</given-names></name><name><surname>Stolzenberg-Solomon</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Comparing metabolite profiles of habitual diet in serum and urine.</article-title><source>Am J Clin Nutr</source>. <year>2016</year>;<volume>104</volume>:<fpage>776</fpage>–<lpage>789</lpage>. <comment>doi: 10.3945/ajcn.116.135301</comment><pub-id pub-id-type="pmid">27510537</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Feunang</surname><given-names>YD</given-names></name><name><surname>Marcu</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Vázquez-Fresno</surname><given-names>R</given-names></name><name><surname>Sajed</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Karu</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>HMDB 4.0: the human metabolome database for 2018.</article-title><source>Nucleic Acids Res</source>. <year>2018</year>;<volume>46</volume>:<fpage>D608</fpage>–<lpage>D617</lpage>. <comment>doi: 10.1093/nar/gkx1089</comment><pub-id pub-id-type="pmid">29140435</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>IJ</given-names></name><name><surname>Daviglus</surname><given-names>ML</given-names></name><name><surname>Chan</surname><given-names>Q</given-names></name><name><surname>Kesteloot</surname><given-names>H</given-names></name><name><surname>Ueshima</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name></person-group>; <collab>INTERMAP Research Group</collab>. <article-title>Glutamic acid, the main dietary amino acid, and blood pressure: the INTERMAP study (International Collaborative Study of Macronutrients, Micronutrients and Blood Pressure).</article-title><source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>221</fpage>–<lpage>228</lpage>. <comment>doi: 10.1161/CIRCULATIONAHA.108.839241</comment><pub-id pub-id-type="pmid">19581495</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Dyer</surname><given-names>AR</given-names></name><name><surname>Appel</surname><given-names>L</given-names></name><name><surname>Dennis</surname><given-names>B</given-names></name><name><surname>Kesteloot</surname><given-names>H</given-names></name><name><surname>Ueshima</surname><given-names>H</given-names></name><name><surname>Okayama</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>Q</given-names></name><name><surname>Garside</surname><given-names>DB</given-names></name><etal/></person-group>. <article-title>Association between protein intake and blood pressure: the INTERMAP Study.</article-title><source>Arch Intern Med</source>. <year>2006</year>;<volume>166</volume>:<fpage>79</fpage>–<lpage>87</lpage>. <comment>doi: 10.1001/archinte.166.1.79</comment><pub-id pub-id-type="pmid">16401814</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>A</given-names></name><name><surname>MacGregor</surname><given-names>A</given-names></name><name><surname>Welch</surname><given-names>A</given-names></name><name><surname>Chowienczyk</surname><given-names>P</given-names></name><name><surname>Spector</surname><given-names>T</given-names></name><name><surname>Cassidy</surname><given-names>A</given-names></name></person-group>. <article-title>Amino acid intakes are inversely associated with arterial stiffness and central blood pressure in women.</article-title><source>J Nutr</source>. <year>2015</year>;<volume>145</volume>:<fpage>2130</fpage>–<lpage>2138</lpage>. <comment>doi: 10.3945/jn.115.214700</comment><pub-id pub-id-type="pmid">26203100</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>A</given-names></name><name><surname>Andrews</surname><given-names>NP</given-names></name><name><surname>Padder</surname><given-names>FA</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><name><surname>Quyyumi</surname><given-names>AA</given-names></name></person-group>. <article-title>Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability.</article-title><source>J Am Coll Cardiol</source>. <year>1999</year>;<volume>34</volume>:<fpage>507</fpage>–<lpage>514</lpage>. <comment>doi: 10.1016/s0735-1097(99)00216-8</comment><pub-id pub-id-type="pmid">10440166</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>VR</given-names></name><name><surname>Ajami</surname><given-names>AM</given-names></name></person-group>. <article-title>Glutamate: an amino acid of particular distinction.</article-title><source>J Nutr</source>. <year>2000</year>;<volume>130</volume>:<fpage>892S</fpage>–<lpage>900S</lpage>. <comment>doi: 10.1093/jn/130.4.892S</comment><pub-id pub-id-type="pmid">10736349</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>KE</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Seidelmann</surname><given-names>SB</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Rhee</surname><given-names>EP</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Rebholz</surname><given-names>CM</given-names></name></person-group>. <article-title>Serum metabolomic signatures of plant-based diets and incident chronic kidney disease.</article-title><source>Am J Clin Nutr</source>. <year>2022</year>;<volume>116</volume>:<fpage>151</fpage>–<lpage>164</lpage>. <comment>doi: 10.1093/ajcn/nqac054</comment><pub-id pub-id-type="pmid">35218183</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Natarajan</surname><given-names>SK</given-names></name><name><surname>Becker</surname><given-names>DF</given-names></name></person-group>. <article-title>Proline mechanisms of stress survival.</article-title><source>Antioxid Redox Signal</source>. <year>2013</year>;<volume>19</volume>:<fpage>998</fpage>–<lpage>1011</lpage>. <comment>doi: 10.1089/ars.2012.5074</comment><pub-id pub-id-type="pmid">23581681</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>N</given-names></name><name><surname>Dickman</surname><given-names>MB</given-names></name><name><surname>Becker</surname><given-names>DF</given-names></name></person-group>. <article-title>Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress.</article-title><source>Free Radic Biol Med</source>. <year>2008</year>;<volume>44</volume>:<fpage>671</fpage>–<lpage>681</lpage>. <comment>doi: 10.1016/j.freeradbiomed.2007.10.054</comment><pub-id pub-id-type="pmid">18036351</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>C</given-names></name><name><surname>Rafii</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>RO</given-names></name><name><surname>Pencharz</surname><given-names>PB</given-names></name></person-group>. <article-title>Arginine can be synthesized from enteral proline in healthy adult humans.</article-title><source>J Nutr</source>. <year>2011</year>;<volume>141</volume>:<fpage>1432</fpage>–<lpage>1436</lpage>. <comment>doi: 10.3945/jn.110.137224</comment><pub-id pub-id-type="pmid">21677074</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>J</given-names></name><name><surname>Teixeira-Santos</surname><given-names>L</given-names></name><name><surname>Pinho</surname><given-names>D</given-names></name><name><surname>Afonso</surname><given-names>J</given-names></name><name><surname>Carvalho</surname><given-names>J</given-names></name><name><surname>de Lourdes Bastos</surname><given-names>M</given-names></name><name><surname>Albino-Teixeira</surname><given-names>A</given-names></name><name><surname>Fraga</surname><given-names>S</given-names></name><name><surname>Sousa</surname><given-names>T</given-names></name></person-group>. <article-title>l-proline supplementation improves nitric oxide bioavailability and counteracts the blood pressure rise induced by angiotensin II in rats.</article-title><source>Nitric Oxide</source>. <year>2019</year>;<volume>82</volume>:<fpage>1</fpage>–<lpage>11</lpage>. <comment>doi: 10.1016/j.niox.2018.10.007</comment><pub-id pub-id-type="pmid">30423454</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names>RL</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Nicholson</surname><given-names>JK</given-names></name><name><surname>Holmes</surname><given-names>E</given-names></name></person-group>. <article-title>Characterization of metabolic responses to healthy diets and association with blood pressure: application to the Optimal Macronutrient Intake Trial for Heart Health (OmniHeart), a randomized controlled study.</article-title><source>Am J Clin Nutr</source>. <year>2018</year>;<volume>107</volume>:<fpage>323</fpage>–<lpage>334</lpage>. <comment>doi: 10.1093/ajcn/nqx072</comment><pub-id pub-id-type="pmid">29506183</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>Cheang</surname><given-names>I</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Inverse association of serum carotenoid levels with prevalence of hypertension in the general adult population.</article-title><source>Front Nutr</source>. <year>2022</year>;<volume>9</volume>:<fpage>971879</fpage>. <comment>doi: 10.3389/fnut.2022.971879</comment><pub-id pub-id-type="pmid">36245540</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landberg</surname><given-names>R</given-names></name><name><surname>Aman</surname><given-names>P</given-names></name><name><surname>Friberg</surname><given-names>LE</given-names></name><name><surname>Vessby</surname><given-names>B</given-names></name><name><surname>Adlercreutz</surname><given-names>H</given-names></name><name><surname>Kamal-Eldin</surname><given-names>A</given-names></name></person-group>. <article-title>Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake.</article-title><source>Am J Clin Nutr</source>. <year>2009</year>;<volume>89</volume>:<fpage>290</fpage>–<lpage>296</lpage>. <comment>doi: 10.3945/ajcn.2008.26709</comment><pub-id pub-id-type="pmid">19056600</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shobako</surname><given-names>N</given-names></name><name><surname>Ishikado</surname><given-names>A</given-names></name><name><surname>Ogawa</surname><given-names>Y</given-names></name><name><surname>Sono</surname><given-names>Y</given-names></name><name><surname>Kusakari</surname><given-names>T</given-names></name><name><surname>Suwa</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Ohinata</surname><given-names>K</given-names></name></person-group>. <article-title>Vasorelaxant and antihypertensive effects that are dependent on the endothelial no system exhibited by rice bran-derived tripeptide.</article-title><source>J Agric Food Chem</source>. <year>2019</year>;<volume>67</volume>:<fpage>1437</fpage>–<lpage>1442</lpage>. <comment>doi: 10.1021/acs.jafc.8b06341</comment><pub-id pub-id-type="pmid">30609899</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-López</surname><given-names>S</given-names></name><name><surname>Sarriá</surname><given-names>B</given-names></name><name><surname>Baeza</surname><given-names>G</given-names></name><name><surname>Mateos</surname><given-names>R</given-names></name><name><surname>Bravo-Clemente</surname><given-names>L</given-names></name></person-group>. <article-title>Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects.</article-title><source>Food Res Int</source>. <year>2014</year>;<volume>64</volume>:<fpage>125</fpage>–<lpage>133</lpage>. <comment>doi: 10.1016/j.foodres.2014.05.043</comment><pub-id pub-id-type="pmid">30011631</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Giuseppe</surname><given-names>R</given-names></name><name><surname>Di Napoli</surname><given-names>I</given-names></name><name><surname>Granata</surname><given-names>F</given-names></name><name><surname>Mottolese</surname><given-names>A</given-names></name><name><surname>Cena</surname><given-names>H</given-names></name></person-group>. <article-title>Caffeine and blood pressure: a critical review perspective.</article-title><source>Nutr Res Rev</source>. <year>2019</year>;<volume>32</volume>:<fpage>169</fpage>–<lpage>175</lpage>. <comment>doi: 10.1017/S0954422419000015</comment><pub-id pub-id-type="pmid">30947761</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesas</surname><given-names>AE</given-names></name><name><surname>Leon-Muñoz</surname><given-names>LM</given-names></name><name><surname>Rodriguez-Artalejo</surname><given-names>F</given-names></name><name><surname>Lopez-Garcia</surname><given-names>E</given-names></name></person-group>. <article-title>The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis.</article-title><source>Am J Clin Nutr</source>. <year>2011</year>;<volume>94</volume>:<fpage>1113</fpage>–<lpage>1126</lpage>. <comment>doi: 10.3945/ajcn.111.016667</comment><pub-id pub-id-type="pmid">21880846</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>S</given-names></name><name><surname>Morinobu</surname><given-names>T</given-names></name><name><surname>Hamamura</surname><given-names>K</given-names></name><name><surname>Hirahara</surname><given-names>F</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><name><surname>Tamai</surname><given-names>H</given-names></name></person-group>. <article-title>The effect of gamma-tocopherol administration on alpha-tocopherol levels and metabolism in humans.</article-title><source>Eur J Clin Nutr</source>. <year>2005</year>;<volume>59</volume>:<fpage>900</fpage>–<lpage>905</lpage>. <comment>doi: 10.1038/sj.ejcn.1602154</comment><pub-id pub-id-type="pmid">15928686</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Frank</surname><given-names>J</given-names></name><name><surname>Riphagen</surname><given-names>IJ</given-names></name><name><surname>Minović</surname><given-names>I</given-names></name><name><surname>Vos</surname><given-names>MJ</given-names></name><name><surname>Eggersdorfer</surname><given-names>ML</given-names></name><name><surname>Navis</surname><given-names>GJ</given-names></name><name><surname>Bakker</surname><given-names>SJL</given-names></name></person-group>. <article-title>Associations of 24 h urinary excretions of α- and γ-carboxyethyl hydroxychroman with plasma α- and γ-tocopherol and dietary vitamin E intake in older adults: the Lifelines-MINUTHE Study.</article-title><source>Eur J Nutr</source>. <year>2022</year>;<volume>61</volume>:<fpage>3755</fpage>–<lpage>3765</lpage>. <comment>doi: 10.1007/s00394-022-02918-8</comment><pub-id pub-id-type="pmid">35718823</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiNicolantonio</surname><given-names>JJ</given-names></name><name><surname>Niazi</surname><given-names>AK</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>O’Keefe</surname><given-names>JH</given-names></name><name><surname>Ventura</surname><given-names>HO</given-names></name></person-group>. <article-title>Thiamine supplementation for the treatment of heart failure: a review of the literature.</article-title><source>Congest Heart Fail</source>. <year>2013</year>;<volume>19</volume>:<fpage>214</fpage>–<lpage>222</lpage>. <comment>doi: 10.1111/chf.12037</comment><pub-id pub-id-type="pmid">23910704</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Sohmiya</surname><given-names>K</given-names></name><name><surname>Kono</surname><given-names>T</given-names></name><name><surname>Terasaki</surname><given-names>F</given-names></name><name><surname>Horie</surname><given-names>R</given-names></name><name><surname>Ohkaru</surname><given-names>Y</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Takai</surname><given-names>S</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Kitaura</surname><given-names>Y</given-names></name></person-group>. <article-title>Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency.</article-title><source>Mol Cell Biochem</source>. <year>2007</year>;<volume>299</volume>:<fpage>23</fpage>–<lpage>35</lpage>. <comment>doi: 10.1007/s11010-005-9032-3</comment><pub-id pub-id-type="pmid">16645728</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Rucker</surname><given-names>RB</given-names></name></person-group>. <article-title>Pantothenic acid.</article-title> In: Erdman JW, Macdonald IA, Zeisel SH, eds. <source>Present Knowledge in Nutrition</source>. <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>; <year>2012</year>. <fpage>375</fpage>–<lpage>390</lpage>.</mixed-citation>
              </ref>
              <ref id="R44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demirci</surname><given-names>B</given-names></name><name><surname>Demir</surname><given-names>O</given-names></name><name><surname>Dost</surname><given-names>T</given-names></name><name><surname>Birincioglu</surname><given-names>M</given-names></name></person-group>. <article-title>Protective effect of vitamin B5 (dexpanthenol) on cardiovascular damage induced by streptozocin in rats.</article-title><source>Bratisl Lek Listy</source>. <year>2014</year>;<volume>115</volume>:<fpage>190</fpage>–<lpage>196</lpage>. <comment>doi: 10.4149/bll_2014_040</comment><pub-id pub-id-type="pmid">24797592</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>PJ</given-names></name><name><surname>Agudiez</surname><given-names>M</given-names></name><name><surname>Molero</surname><given-names>D</given-names></name><name><surname>Martin-Lorenzo</surname><given-names>M</given-names></name><name><surname>Baldan-Martin</surname><given-names>M</given-names></name><name><surname>Santiago-Hernandez</surname><given-names>A</given-names></name><name><surname>García-Segura</surname><given-names>JM</given-names></name><name><surname>Madruga</surname><given-names>F</given-names></name><name><surname>Cabrera</surname><given-names>M</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations.</article-title><source>J Mol Med (Berl)</source>. <year>2020</year>;<volume>98</volume>:<fpage>1603</fpage>–<lpage>1613</lpage>. <comment>doi: 10.1007/s00109-020-01976-x</comment><pub-id pub-id-type="pmid">32914213</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Yi</surname><given-names>W</given-names></name><name><surname>Dai</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group>. <article-title>UPLC-MS-based urine nontargeted metabolic profiling identifies dysregulation of pantothenate and CoA biosynthesis pathway in diabetic kidney disease.</article-title><source>Life Sci</source>. <year>2020</year>;<volume>258</volume>:<fpage>118160</fpage>. <comment>doi: 10.1016/j.lfs.2020.118160</comment><pub-id pub-id-type="pmid">32730837</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>RH</given-names></name><name><surname>Tatum</surname><given-names>SM</given-names></name><name><surname>Symons</surname><given-names>JD</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name><name><surname>Holland</surname><given-names>WL</given-names></name></person-group>. <article-title>Ceramides and other sphingolipids as drivers of cardiovascular disease.</article-title><source>Nat Rev Cardiol</source>. <year>2021</year>;<volume>18</volume>:<fpage>701</fpage>–<lpage>711</lpage>. <comment>doi: 10.1038/s41569-021-00536-1</comment><pub-id pub-id-type="pmid">33772258</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fretts</surname><given-names>AM</given-names></name><name><surname>Jensen</surname><given-names>PN</given-names></name><name><surname>Hoofnagle</surname><given-names>A</given-names></name><name><surname>McKnight</surname><given-names>B</given-names></name><name><surname>Howard</surname><given-names>BV</given-names></name><name><surname>Umans</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Sitlani</surname><given-names>C</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name><name><surname>King</surname><given-names>IB</given-names></name><etal/></person-group>. <article-title>Plasma ceramide species are associated with diabetes risk in participants of the strong heart study.</article-title><source>J Nutr</source>. <year>2020</year>;<volume>150</volume>:<fpage>1214</fpage>–<lpage>1222</lpage>. <comment>doi: 10.1093/jn/nxz259</comment><pub-id pub-id-type="pmid">31665380</pub-id></mixed-citation>
              </ref>
              <ref id="R49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>LR</given-names></name><name><surname>Xanthakis</surname><given-names>V</given-names></name><name><surname>Duncan</surname><given-names>MS</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Friedrich</surname><given-names>N</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Sidhu</surname><given-names>R</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Ceramide remodeling and risk of cardiovascular events and mortality.</article-title><source>J Am Heart Assoc</source>. <year>2018</year>;<volume>7</volume>:<fpage>e007931</fpage>. <comment>doi: 10.1161/JAHA.117.007931</comment><pub-id pub-id-type="pmid">29728014</pub-id></mixed-citation>
              </ref>
              <ref id="R50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilvo</surname><given-names>M</given-names></name><name><surname>Meikle</surname><given-names>PJ</given-names></name><name><surname>Pedersen</surname><given-names>ER</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><name><surname>Dhar</surname><given-names>I</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Schöttker</surname><given-names>B</given-names></name><name><surname>Lääperi</surname><given-names>M</given-names></name><name><surname>Kauhanen</surname><given-names>D</given-names></name><name><surname>Koistinen</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.</article-title><source>Eur Heart J</source>. <year>2020</year>;<volume>41</volume>:<fpage>371</fpage>–<lpage>380</lpage>. <comment>doi: 10.1093/eurheartj/ehz387</comment><pub-id pub-id-type="pmid">31209498</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>DD</given-names></name><name><surname>Toledo</surname><given-names>E</given-names></name><name><surname>Hruby</surname><given-names>A</given-names></name><name><surname>Rosner</surname><given-names>BA</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Razquin</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Ruiz-Canela</surname><given-names>M</given-names></name><name><surname>Guasch-Ferré</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Plasma ceramides, mediterranean diet, and incident cardiovascular disease in the PREDIMED trial.</article-title><source>Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>2028</fpage>–<lpage>2040</lpage>. <comment>doi: 10.1161/CIRCULATIONAHA.116.024261</comment><pub-id pub-id-type="pmid">28280233</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <label>52.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manach</surname><given-names>C</given-names></name><name><surname>Williamson</surname><given-names>G</given-names></name><name><surname>Morand</surname><given-names>C</given-names></name><name><surname>Scalbert</surname><given-names>A</given-names></name><name><surname>Rémésy</surname><given-names>C</given-names></name></person-group>. <article-title>Bioavailability and bioefficacy of polyphenols in humans. I. review of 97 bioavailability studies.</article-title><source>Am J Clin Nutr</source>. <year>2005</year>;<volume>81</volume>:<fpage>230S</fpage>–<lpage>242S</lpage>. <comment>doi: 10.1093/ajcn/81.1.230S</comment><pub-id pub-id-type="pmid">15640486</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <label>53.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>C-HE</given-names></name><name><surname>Siskos</surname><given-names>AP</given-names></name><name><surname>Maitre</surname><given-names>L</given-names></name><name><surname>Robinson</surname><given-names>O</given-names></name><name><surname>Athersuch</surname><given-names>TJ</given-names></name><name><surname>Want</surname><given-names>EJ</given-names></name><name><surname>Urquiza</surname><given-names>J</given-names></name><name><surname>Casas</surname><given-names>M</given-names></name><name><surname>Vafeiadi</surname><given-names>M</given-names></name><name><surname>Roumeliotaki</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Determinants of the urinary and serum metabolome in children from six European populations.</article-title><source>BMC Med</source>. <year>2018</year>;<volume>16</volume>:<fpage>202</fpage>. <comment>doi: 10.1186/s12916-018-1190-8</comment><pub-id pub-id-type="pmid">30404627</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>ML</given-names></name><name><surname>Maliniak</surname><given-names>ML</given-names></name><name><surname>Stevens</surname><given-names>VL</given-names></name><name><surname>Carter</surname><given-names>BD</given-names></name><name><surname>Hodge</surname><given-names>RA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>. <article-title>Metabolomic markers of healthy dietary patterns in US postmenopausal women.</article-title><source>Am J Clin Nutr</source>. <year>2019</year>;<volume>109</volume>:<fpage>1439</fpage>–<lpage>1451</lpage>. <comment>doi: 10.1093/ajcn/nqy385</comment><pub-id pub-id-type="pmid">31051511</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>EA</given-names></name><name><surname>Wong</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Steffen</surname><given-names>LM</given-names></name><name><surname>Seidelmann</surname><given-names>SB</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Rebholz</surname><given-names>CM</given-names></name></person-group>. <article-title>Serum metabolites associated with healthy diets in African Americans and European Americans.</article-title><source>J Nutr</source>. <year>2021</year>;<volume>151</volume>:<fpage>40</fpage>–<lpage>49</lpage>. <comment>doi: 10.1093/jn/nxaa338</comment><pub-id pub-id-type="pmid">33244610</pub-id></mixed-citation>
              </ref>
              <ref id="R56">
                <label>56.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>ME</given-names></name><name><surname>Song</surname><given-names>RJ</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Gerszten</surname><given-names>RE</given-names></name><name><surname>Ngo</surname><given-names>D</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><name><surname>Corlin</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Xanthakis</surname><given-names>V</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><etal/></person-group>. <article-title>Proteomic and metabolomic correlates of healthy dietary patterns: the framingham heart study.</article-title><source>Nutrients</source>. <year>2020</year>;<volume>12</volume>:<fpage>1476</fpage>. <comment>doi: 10.3390/nu12051476</comment><pub-id pub-id-type="pmid">32438708</pub-id></mixed-citation>
              </ref>
              <ref id="R57">
                <label>57.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner-Golbs</surname><given-names>A</given-names></name><name><surname>Neuber</surname><given-names>S</given-names></name><name><surname>Kamlage</surname><given-names>B</given-names></name><name><surname>Christiansen</surname><given-names>N</given-names></name><name><surname>Bethan</surname><given-names>B</given-names></name><name><surname>Rennefahrt</surname><given-names>U</given-names></name><name><surname>Schatz</surname><given-names>P</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name></person-group>. <article-title>Effects of long-term storage at −80 °C on the human plasma metabolome.</article-title><source>Metabolites</source>. <year>2019</year>;<volume>9</volume>:<fpage>99</fpage>. <comment>doi: 10.3390/metabo9050099</comment><pub-id pub-id-type="pmid">31108909</pub-id></mixed-citation>
              </ref>
              <ref id="R58">
                <label>58.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remer</surname><given-names>T</given-names></name><name><surname>Montenegro-Bethancourt</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name></person-group>. <article-title>Long-term urine biobanking: storage stability of clinical chemical parameters under moderate freezing conditions without use of preservatives.</article-title><source>Clin Biochem</source>. <year>2014</year>;<volume>47</volume>:<fpage>307</fpage>–<lpage>311</lpage>. <comment>doi: 10.1016/j.clinbiochem.2014.09.009</comment><pub-id pub-id-type="pmid">25239781</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
